22PESR1 mutations are similarly prevalent in newly metastatic and loco-regional recurrence of endocrine-treated breast cancer patients and carry worse prognosis. (13th May 2019) - Nili Gal Yam, E; Zundelevich, A; Dadiani, M; Itay, A; Sela, T; Gadot, M; Kahana, S; Pavlovsky, A; Barshack, I; Kaufman, B